Image for illustrative purposes / FLUX An analysis found that artificial intelligence (AI) may amplify and reproduce errors rather than resolve defects in clinical trials. According to the biotech news outlet Fierce Biotech on the 19th (local time), clinical trial data company Ph
2026-05-20
Image for illustrative purposes / FLUX Takeda has been ordered to pay more than 1 trillion won in damages after being found liable for colluding with a competitor to block the launch of a generic version of its constipation treatment. According to pharmaceutical trade publication
2026-05-19
Image for illustrative purposes / FLUX India’s HAB Pharma has set a growth target of quintupling its revenue by 2030 through the acquisition of a peer company. According to pharmaceutical trade publication Express Pharma on the 19th local time, Indian pharmaceutical company HAB P
2026-05-19
GeneOne Life Science GeneOne Life Science (011000) surged to the daily price limit as the Hantavirus theme reignited, but the company’s filings contained not a single line on a new Hantavirus-related catalyst. According to data from the Korea Exchange and the Financial Supervisor
2026-05-19
LIGACHEM BIO LIGACHEM BIO issued a message saying that the decline in its share price was “not a change in fundamentals,” but its first-quarter results disclosed during the same period point to both a return to losses and a decline in revenue. LIGACHEM BIO (141080)’s investor rel
2026-05-19
Image for illustrative purposes / FLUX EuBiologics will supply UNICEF with KRW 8.5 billion worth of the oral cholera vaccine ‘EuBiologics-S.’ EuBiologics said in a disclosure on May 19 that it had signed a KRW 8.50491 billion supply agreement with UNICEF for ‘EuBiologics-S.’ The
2026-05-19
Image for illustrative purposes / FLUX Asta has decided to acquire assets worth 8.3 billion won to strengthen its mass spectrometry-based diagnostic business capabilities. Asta disclosed that its board of directors resolved on the 19th to acquire tangible and intangible assets wo
2026-05-19
Image for illustrative purposes / FLUX A US biotech that fell into financial difficulty after failing to develop a treatment for a rare disease is seeking to survive through a reverse merger. According to filings with the US Securities and Exchange Commission (SEC) and other sour
2026-05-19
Image for illustrative purposes / FLUX Huons will absorb its R&D-focused subsidiary Huons Lab to strengthen its new drug pipeline and secure competitiveness in the biopharmaceutical business. Huons announced on the 18th that its board of directors had resolved to absorb Huons Lab
2026-05-18
Image for illustrative purposes / FLUX Regeneron has signed a large-scale agreement worth approximately $2.4 billion with Parabilis Medicines to develop antibody-drug conjugate (ADC)-like therapeutics that target sites that have been difficult to reach with existing drugs. Accord
2026-05-18
Peptone nears end of two-year Lilly technology evaluation…follow-on deal could be pivotal
HLB Pharmaceutical Completes 60.8 Billion Won Rights Offering, Bets on New Hyangnam Plant as Management Participation Grows
Song Young-sook sells 86 billion won stake; buyer is daughter’s one-person company — Is a second round of Hanmi control battle looming?
